Onconetix (ONCO) Proxy Filing summary

Executive summary

• The proxy filing details an annual meeting to vote on seven key proposals, including director elections, amendments to the equity incentive plan, a reverse stock split, conversions of preferred stock, share issuances related to the Proteomedix (PMX) acquisition, auditor ratification, and potential adjournment to solicit more proxies if needed.

• The company recently acquired Proteomedix AG, making it a wholly owned subsidiary, and issued common and preferred stock as consideration, with the preferred stock convertible into a significant majority of the company's outstanding shares upon shareholder approval.

• The company is currently focused on commercializing Proclarix, a prostate cancer diagnostic, and has paused commercialization of ENTADFI due to financial constraints and is exploring strategic alternatives for that asset.

• The company faces substantial financial challenges, including a working capital deficit, accumulated losses, and doubts about its ability to continue as a going concern without additional capital.

• The board unanimously recommends voting in favor of all proposals, which are designed to address Nasdaq compliance, capital structure, and strategic growth.

Voting matters and shareholder proposals

• Election of two Class III directors for a three-year term.

• Amendment to the 2022 Equity Incentive Plan to increase the share reserve.

• Reverse stock split at a ratio between 1-for-30 and 1-for-60 to regain Nasdaq compliance.

• Approval of conversion of Series A Preferred Stock into common stock, and approval of the issuance of common stock upon conversion of Series B Preferred Stock and in connection with the PMX Financing.

• Ratification of EisnerAmper LLP as the independent auditor for 2024.

• Authorization to adjourn the meeting if necessary to solicit additional proxies.

Board of directors and corporate governance

• The board is composed of five members, with staggered three-year terms and a mix of independent and management directors.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, each with defined charters and responsibilities.

• The board is responsible for risk oversight, strategic guidance, and compliance.

• The post-transaction board will include two designees from the company and three from Proteomedix.